Quick Answer
VOLITIONRX LTD reported Diluted EPS of $0.31 per share (loss) for fiscal year 2024.
VOLITIONRX LTD Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$0.31 | +38.0% |
| 2023 | -$0.50 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.05 | +28.6% | +16.7% |
| June 30, 2025 | -$0.06 | +25.0% | +0.0% |
| March 31, 2025 | -$0.06 | +40.0% | +14.3% |
| September 30, 2024 | -$0.07 | — | +12.5% |
| June 30, 2024 | -$0.08 | — | +20.0% |
| March 31, 2024 | -$0.10 | — | +37.5% |
| September 30, 2015 | -$0.16 | +63.6% | -60.0% |
| June 30, 2015 | -$0.10 | -266.7% | +77.3% |
- VOLITIONRX LTD showed an increase of +38.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2024 period, VOLITIONRX LTD’s diluted eps has grown by 38.0% (from $0.50 per share (loss) to $0.31 per share (loss)).
- The most recent figure is from VOLITIONRX LTD’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: